INTRODUCTION
Deficiency of the enzyme 5,10-methylene tetahydrofolate reductase (EC 1.1.1.68) leads clinically to neurologic dysfunction of variable type and severity, and biochemically to homocystinuria, homocystinemia, and decreased plasma and intracellular concentrations of methionine (1) . The enzyme catalyzes the essentially irreversible reduction of 5,10-methylenetetrahydrofolate (5,10-CH2-H4PteGlu) to 5-methyltetrahydrofolate (5-CH3-H4PteGlu) (2). 5-CH3H4PteGlu serves as the methyl donor in the conversion of homocysteine (HG)1 to methionine (Met) by the cobalamin-dependent enzyme, methionine synthetase. 5,10-CH2-H4-PteGlu reductase deficiency has been shown to result in reduced 5-CH3-H4PteGlu levels in serum, erythrocytes, and brain (3) , and a diminished proportion of total intracellular folates as 5-CH3-H4PteGlu in fibroblasts cultured from these patients (4) . Deficiency of 5-CH3-H4PteGlu would be expected to result in reduced Met synthetase activity leading to diminished Met biosynthesis, but this has not yet been demonstrated directly although it is implied by two findings. First, skin fibroblasts from 5,10-CH2-H4PteGlu reductase-deficient patients grow less rapidly (5) or, under more stringent conditions, not at all (1) when HC replaces Met in culture medium. Second, tissue amino acid analysis reported only for brain and liver ofone patient indicated a reduced concentration of Met (6) .
Activity of 5,10-CH2-H4PteGlu reductase has been measured in crude extracts of skin fibroblasts or leukocytes using a coupled reaction that proceeds in the reverse direction from the physiologic reaction (2) . The extent of 5,10-CH2-H4PteGlu reductase deficiency measured in this way has correlated imperfectly with the severity of the clinical and metabolic abnormalities in the patients from whom the cells were derived. To test the hypothesis that the clinical and metabolic abnormalities would more closely parallel the degree of secondary disturbance of the Met synthetase reaction, we undertook to measure the Met biosynthetic capacity in a whole cell system of fibroblasts and lymphoblasts by means Ill. ) and incubated at 37°C for 4-8 h. The assay was terminated by placing the dishes on ice and quickly washing the cells twice with 3 ml of ice-cold PBS, leaving an additional 0.5 ml of PBS in the dishes. Cells were removed from the surface by scraping with a teflon policeman and added to trichlotoacetic acid (TCA) to yield a final concentration of5%. The cells were extracted on ice for 30 min, then heated for 30 min at 80°C to solubilize the DNA and RNA (9) . The tubes were cooled on ice for 15 min and the resulting protein precipitate, free of nucleic acids, was washed three times with 10% TCA. The protein pellets were resuspended in 0.4 ml of ultra-pure 6 N HCI (Alfa Div., Ventron Corp., Danvers, Mass.) and hydrolyzed for 24 h at 110°C. The resulting hydrolysate was concentrated by vacuum-evaporation to dryness with a heatlamp and resuspended in 50 ,ul of H20. A 10-ul sample was streaked on cellulose thin-layer chromatography plates with fluorescent indicator (Eastman Kodak Co., Rochester, N. Y.). Met (and its breakdown products Met sulfoxide and Met sulfone) were separated from serine and cysteine (and its products cystine and cysteic acid) in a phenol:ethanol:H20: NH40H (65:20:20:2) one-dimensional solvent system. Since serine condenses with HC to form cystathionine, which is converted to cysteine, any label that appears in cysteine actually originates from serine. The cold carrier amino acids were visualized using UV light after spraying the plates with fluorescamine (Kontes Co., Vineland, N. J.) and the spots cut out and quantified by liquid 14 ,uM. After the TCA precipitation, the precipitate was collected on GF/A glass microfiber filters (Whatman, Inc., Clifton, N. J.) washed three times with 10% TCA and once with 0.1 N HCI, dried and counted in Econofluor at 35% efficiency. Protein was determined by the method of Lowry (10) in a third set of replicate plates. Amino acid analysis by ion exchange chromatography was performed on a Beckman amino acid analyzer (Beckman Instruments, Inc., Fullerton, Calif.).
Lymphoblasts were maintained in logarithmic growth until the day of assay when they were recovered from the RPMI medium by centrifugation and resuspended at a density of 1.5 x 106 cells/ml in the Met-free, HC-supplemented medium. 1 The results of our whole-cell assay for Met biosyn- (7, 6 , and 4% of controls, respectively) even though cell line MGF735 has 32% of normal enzyme activity in the cell extract.
In Table III the two 5,10-CH2-H4PteGlu reductasedeficient lymphoblast lines are compared with two control lines. Cell line MGL30 has 36% of the Met synthetic capacity ofthe control lines, and this corresponds closely to the fibroblast line, which has 43% of the control value and is derived from the same patient (MGF548). However, MGL28 has 26% of the Met synthetic capacity ofthe control lymphoblast lines, and this does not correspond well to the fibroblast line derived from the same patient (MGF451) who has 11% of control values. This same assay was performed in two controls and three of the 5,10-CH2-H4PteGlu reductase-deficient fibroblast lines at low concentrations of Met (1, 3, 10, and 30 ,uM) . Although the apparent rates of Met synthesis were lower owing to the dilutional effect of the unlabeled Met, the differences between the normal and the deficient lines remain unchanged. Since the activity of 5,10-CH2-H4PteGlu reductase is known to be higher in confluent cells than in logarithmically growing cells (15) , the assay was also performed once in three normal and in two deficient fibroblast lines after 7 d at confluency. Although one of the normal lines doubled its rate of Met biosynthesis compared with the usual assay conditions at late log growth, the other two normal lines showed no significant change. The two reductasedeficient lines showed small but insignificant increases in rates of Met biosynthesis.
All the 5,10-CH2H4PteGlu reductase-deficient cell lines had normal Met synthetase (5-CH3-H4PteGlu: homocysteine cobalamin methyltransferase) activity (16) . To be certain that fibroblast line MGF735 might not represent a deficiency of some other enzyme of the folate pathway, the cellular extract was also assayed for activity of 5,10-CH=H4PteGlu cyclohydrolase (17), 5,10-CH2-H4PteGlu dehydrogenase (17) , serine hydroxymethyltransferase (18) , and 10-CHO-H4PteGlu synthetase (17) . In each instance the activity was similar to control values (data not shown). In addition, line MGF735 exhibited the same poor growth pattern in Met-free, HC-supplemented medium as did other 5,10-CH2-H4PteGlu reductase-deficient fibroblast lines. The detailed description of patient M.S. is in preparation by Dr. S. Cederbaum.2 DISCUSSION The studies we report here clearly demonstrate that fibroblasts and lymphoblasts from 5,10-CH2-H4PteGlu reductase-deficient patients exhibit decreased capacity to synthesize Met from HC. The magnitude of the defect in Met synthesis accurately reflects the clinical status ofthe patients from whom the cells were derived. Met synthesis from HC in human fibroblasts is completely dependent on 5,10-CH2-H4PteGlu reductase activity since there is no detectable betaine homocysteine methyltransferase activity (19) .
The disparity between the measured Met synthesis (average, 38% of normal) and the measured residual enzyme activity in the extracts (18% of normal) in the cells derived from the mildly affected patients is striking and of interest. Met synthesis from HC is directly under the control of the enzyme Met synthetase. The product of the 5,10-CH2-H4PteGlu reductase reaction is 5-CH3-H4PteGlu, a substrate along with HC in the Met synthetase reaction. It appears that 18% of normal reductase activity can generate enough 5-CH3-H4Pte-Glu to support Met synthesis at a rate -40% of normal. Perhaps only 30-40% of 5,10-CH2H4PteGlu reductase activity is required to maintain Met synthesis at near normal rates and hence such a mutation would not be clinically apparent. This is consistent with our observation that fibroblasts from heterozygous parents of reductase-deficient patients grow at normal rates in medium in which HC replaces Met (unpublished data).
As has been widely believed and elegantly demonstrated in the case of Yoshida's studies (20) on glucose-6-phosphate dehydrogenase deficiency, the residual enzyme activity measured in an in vitro extract under potentially nonphysiologic conditions may correlate poorly with the severity of the phenotypic disturbance. He showed that a measurement of the physiologic activity of the enzyme may correlate better with the clinical status of the patient. Although patient M.S. in our studies is severely affected clinically, her fibroblast line (MGF735) has 32% of normal 5,10-CH2H4PteGlu reductase activity as measured in a crude cell extract. The Met synthetic capacity of her fibroblast line, however, is only 6.5% of normal values and very similar to the other two lines derived from severely affected children.
Patient S.S. died at 9 mo of age. Her fibroblast line (MGF876) synthesized Met at 4% of normal values, the lowest rate of any line studied. The data suggest that >4% of normal Met synthetic capacity as measured in our whole cell system is necessary for survival.
The poor correlation of Met synthetic rates in lymphoblast line MGL28, 26% of normal, with the Met synthetic function in the fibroblast line derived from the same patient, MGF451, 11% of normal, is unexplained. It is known that the transformation of human fibroblasts by simian virus 40 may also be associated with altered rates of Met biosynthesis and Met requirements (21) . Perhaps Epstein-Barr virus transformation of human lymphocytes likewise is associated with changes in rates of Met biosynthesis. Alternatively, this discrepancy might be due to tissue specific differences in expression of the enzyme defect caused by factors such as those identified by Yoshida.
Patients with 5,10-CH2-H4PteGlu reductase deficiency present clinically with neurologic dysfunction of variable degree. The etiology of their neurologic disturbance is unclear but may relate to altered metabolism of neurotransmitters (13) . Many of the neurotransmitters undergo methylation in their synthesis and the main intracellular donor of methyl groups is S-adenosylmethionine (AdoMet). Methionine and adenosinetriphosphate are the precursors of AdoMet. The brain, like any other organ, meets its requirement for Met either by uptake from the blood or endogenous synthesis (22) . We have demonstrated decreased Met synthetic capacity in 5,10-CH2-H4PteGlu reductase-deficient fibroblasts and lymphoblasts and postulate a similar decrease in the brain cells of these patients, leading to inadequate AdoMet generation for normal neurotransmitter synthesis.
